onr:"swepub:oai:DiVA.org:oru-33867"
Sökning: onr:"swepub:oai:DiVA.org:oru-33867" > Probiotic and synbi...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Probiotic and synbiotic safety in infants under two years of age
-
- van den Nieuwboer, M (författare)
- Athena Inst, Vrije Univ Amsterdam, Amsterdam, Netherlands; Swammerdam Inst Life Sci, Univ Amsterdam, Amsterdam, Netherlands
-
- Claassen, E (författare)
- Athena Inst, Vrije Univ Amsterdam, Amsterdam, Netherlands; Dept Virosci, Erasmus MC, Rotterdam, Netherlands
-
- Morelli, L (författare)
- Ist Microbiol, Univ Cattolica SC, Piacenza, Italy
- visa fler...
- visa färre...
- (creator_code:org_t)
- Wageningen : Wageningen Academic Publishers, 2014
- 2014
- Engelska.
- Ingår i: Beneficial Microbes. - Wageningen : Wageningen Academic Publishers. - 1876-2883 .- 1876-2891. ; 5:1, s. 45-60
- Tidskriftsartikel (refereegranskat)
Abstract
Ämnesord
Stäng
- In this study, we systematically evaluated safety aspects in clinical trials with probiotics and synbiotics in young infants (0-2 years of age). This study is an update of earlier reports and covers the recent literature from 2008-2013. The safety evaluation is performed along the Common Terminology Clinical Adverse Events (CTCAE) version 4.0 scale, hereby also providing guidance for future studies. Safety aspects are represented and related to number of participants per probiotic strain/culture, study duration, dosage, clinical condition and selected afflictions. The results show a deficiency in the precise reporting and classification of adverse events in most studies. Analysis of 57 clinical trials with probiotics and synbiotics in combination with eight follow-up studies indicate that probiotic administration to infants between 0 and 24 months is safe with regard to the evaluated strains in infants with a particular health status or susceptibility. Most adverse events and serious adverse events were considered unrelated to the study product, and there were no major safety concerns. Almost all studies concluded that none of the adverse effects were related to the study product; the study products are generally well tolerated. Finally, inconsistent, imprecise and potentially incomplete reporting as well as the variation in probiotic strains, dosages, administration regimes, study populations and reported outcomes, greatly limit the generalizability of conclusions and argue convincingly for obligatory and standardised behaviour on adverse events (CTCAE) reporting in 'food' studies.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Mikrobiologi inom det medicinska området (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Microbiology in the medical area (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Hälsovetenskap -- Näringslära (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Health Sciences -- Nutrition and Dietetics (hsv//eng)
Nyckelord
- prebiotics; probiotics; health benefits; food safety legislation; children
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- van den Nieuwboe ...
- Claassen, E
- Morelli, L
- Guarner, F
- Brummer, Robert ...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Medicinska och f ...
- och Mikrobiologi ino ...
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Hälsovetenskap
- och Näringslära
- Artiklar i publikationen
- Beneficial Micro ...
- Av lärosätet
- Örebro universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
